A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Phase 2 Completed 26 enrolled Priovant Therapeutics, Inc.

RandomizedParallel-groupTriple-blindOther

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Timeline

Start: 2022-11-14
Primary completion: 2024-07-30
Completion: 2024-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brepocitinib	Small molecule	—	Oral

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Summary

Timeline

Drugs

Indications